Data-Driven Estimation of Heavy-Truck Residual Value at the Buy-Back

In a context of deep transformation of the entire automotive industry, starting from pervasive and native connectivity, commercial vehicles (heavy, light, and buses) are generating and transmitting much more data than passenger cars, with a much higher expected value, motivated by the higher costs of the vehicles and their added-value related businesses, such as logistics, freight, and transportation management. This paper presents a data-driven and unsupervised methodology to provide a descriptive model assessing the residual value estimates of heavy trucks subject to buy-back. A huge amount of telematics data characterizing the actual usage of commercial vehicles is jointly analyzed with different external conditions (e.g., altimetry), affecting the truck's performance to estimate the devaluation of the vehicle at the buy-back. The proposed approach has been evaluated on a large set of real-world heavy trucks to demonstrate its effectiveness in correctly assessing the real status of wear and residual value at the end of leasing contracts, to provide a few and quantitative insights through an informative, interactive and user-friendly dashboard to make a proper decision on the next business strategies to be adopted. The proposed solution has already been deployed by a private company within its data analytics services since (1) an interpretable descriptive model of the main factors/parameters and corresponding weights affecting the residual value is provided and (2) the experimental results confirmed the promising outcomes of the proposed data-driven methodology

Protocol for the development of a CONSORT extension for RCTs using cohorts and routinely collected health data.

Background: Randomized controlled trials (RCTs) are often complex and expensive to perform. Less than one third achieve planned recruitment targets, follow-up can be labor-intensive, and many have limited real-world generalizability. Designs for RCTs conducted using cohorts and routinely collected health data, including registries, electronic health records, and administrative databases, have been proposed to address these challenges and are being rapidly adopted. These designs, however, are relatively recent innovations, and published RCT reports often do not describe important aspects of their methodology in a standardized way. Our objective is to extend the Consolidated Standards of Reporting Trials (CONSORT) statement with a consensus-driven reporting guideline for RCTs using cohorts and routinely collected health data. Methods: The development of this CONSORT extension will consist of five phases. Phase 1 (completed) consisted of the project launch, including fundraising, the establishment of a research team, and development of a conceptual framework. In phase 2, a systematic review will be performed to identify publications (1) that describe methods or reporting considerations for RCTs conducted using cohorts and routinely collected health data or (2) that are protocols or report results from such RCTs. An initial "long list" of possible modifications to CONSORT checklist items and possible new items for the reporting guideline will be generated based on the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) and The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statements. Additional possible modifications and new items will be identified based on the results of the systematic review. Phase 3 will consist of a three-round Delphi exercise with methods and content experts to evaluate the "long list" and generate a "short list" of key items. In phase 4, these items will serve as the basis for an in-person consensus meeting to finalize a core set of items to be included in the reporting guideline and checklist. Phase 5 will involve drafting the checklist and elaboration-explanation documents, and dissemination and implementation of the guideline. Discussion: Development of this CONSORT extension will contribute to more transparent reporting of RCTs conducted using cohorts and routinely collected health data